Ebola: Early Tests Of Two Vaccines In Liberia
The first tests of the two vaccines against Ebola considered most promising began Monday in Liberia, one of the most affected by the virus, announced the US-Liberian cooperation PREVAIL, which leads them.
This is ChAd3, developed by the British firm GSK (GlaxoSmithKline) with the American Institute of Allergy and Infectious Diseases (NIAID), and rVSV-ZEBOV of the Public Health Agency of Canada (PHAC), which US company Merck acquired the rights and cooperates with the American company NewLink Genetics. “Both vaccines have been shown to prevent Ebola in animals and have been determined safe in human trials on smaller safety studies in Africa, Europe and America,” recalled Prevail (Partnership for Research on Ebola Vaccines for Liberia) in a statement.
“The test begins at the Redemption Hospital in Monrovia. Other sites will be added in other hospitals in Monrovia and its neighborhood after the first 600 participants,” according to the text.
The tests were officially launched at this hospital on Sunday at a ceremony attended by Vice President Joseph Boaikai. “We hope this science project we are launching today will provide an answer to the mystery that surrounds this disease” for which there is no licensed vaccine, Dr. Boaikai said.
The director of the Wellcome Trust, the UK, which funds research against Ebola, Jeremy Farrar said it was “fantastic that these first large-scale vaccine trials take place in Liberia, a country that has suffered greatly at the height of the epidemic ‘, with at least 3700 deaths on some 9000 identified in the epidemic.
The researchers, under the supervision of NIAID, aim a sample of 27 000 men and women in good health, aged 18 years and older.
According to Prevail, these vaccines can cause pain, inflammation or swelling in the arm, as well as fever, headache, fatigue, but these side effects “were mild or moderate and resolved themselves “.